Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...

In fact, leukemia ... why my white blood cell count was so high. I was diagnosed with acute myeloid leukemia, and the ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...

The Mass General Brigham Gene and Cell Therapy Institute, a hub of innovation dedicated to accelerating groundbreaking research, conducting clinical trials and developing FDA-approved treatments, ...

NBA referee Scott Wall was diagnosed with acute myeloid ... blood cell count, extent of bone damage, and the body’s response ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...